NEW YORK ( TheStreet) -- Meridian Bioscience (Nasdaq: VIVO) hit a new 52-week low Wednesday as it is currently trading at $16.78, below its previous 52-week low of $16.80 with 186,340 shares traded as of 2:36 p.m. ET. Average volume has been 319,800 shares over the past 30 days.

Meridian Bioscience has a market cap of $716.3 million and is part of the health care sector and drugs industry. Shares are down 24.7% year to date as of the close of trading on Tuesday.

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The company has a P/E ratio of 28.1, above the average drugs industry P/E ratio of 27.7 and above the S&P 500 P/E ratio of 17.7.
  • Practice your VIVO trading strategies and win cash in our stock game.

TheStreet Ratings rates Meridian Bioscience as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, premium valuation and weak operating cash flow. You can view the full Meridian Bioscience Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

3 Undiscovered, Undervalued Health Care Stocks Poised to Outperform the Sector in 2016

3 Undiscovered, Undervalued Health Care Stocks Poised to Outperform the Sector in 2016

Insider Trading Alert - VIVO, CCG And PDCE Traded By Insiders

Insider Trading Alert - VIVO, CCG And PDCE Traded By Insiders

Meridian Bioscience (VIVO) Weak On High Volume

Meridian Bioscience (VIVO) Weak On High Volume

Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom

Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom

Meridian Bioscience (VIVO) Upgraded From Hold to Buy

Meridian Bioscience (VIVO) Upgraded From Hold to Buy